Microsoft has initiated a 4% workforce reduction, equating to approximately 9,000 positions, in response to macroeconomic pressures and evolving strategic priorities. This follows a...
SINGAPORE, July 3, 2025 /PRNewswire/ -- Vistra, a leading provider of essential business solutions that help organisations to invest and grow efficiently and compliantly...
CHICAGO and PUNE, India, July 2, 2025 /PRNewswire/ --
What's Behind the Surge in the US$3.22 Billion Feed Phosphate Market?
The Feed Phosphate Market is projected to be...
NEWTOWN SQUARE, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the pricing of an underwritten public offering of 2,482,692 shares of its common stock at a price to the public of $19.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 1,363,469 shares of its common stock at a price to the public of $19.4999, which represents the per share public offering price for the shares of common stock less $0.0001 per share exercise price for each pre-funded warrant. The gross proceeds to ArriVent from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be approximately $75 million. In addition, ArriVent has granted the underwriters a 30-day option to purchase up to an additional 576,923 shares of its common stock on the same terms and conditions. All of the securities are being offered by ArriVent.
SARATOGA, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in its capsule endoscopy solutions, today announced the pricing of its initial public offering of 5,500,000 shares of common stock at a public offering price of $5.00 per share. The shares are expected to begin trading on the Nasdaq Capital Market on July 2, 2025 under the ticker symbol “CV.” The offering is expected to close on July 3, 2025 subject to the satisfaction of customary closing conditions.
Live Shopping App Palmstreet Launches Collectibles Market with Coveted Labubu Resellers and Daily Prize Campaign
MENLO PARK, Calif., July 1, 2025 /PRNewswire/ -- Palmstreet, the...
Recruitment initiated into the Phase 2 opaganib plus darolutamide study in patients with advanced prostate cancer, sponsored by ANZUP, and supported by Bayer and...
Danville, California-based team brings $1.1 billion in assets to Steward Partners
NEW YORK, July 1, 2025 /PRNewswire/ -- Steward Partners, a full-service, employee-owned, independent financial...
SAN FRANCISCO, July 1, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the...
Singapore , July 01, 2025 (GLOBE NEWSWIRE) -- YY Group Holding Limited (NASDAQ: YYGH) (“YY Group,” “YYGH,” or the “Company”), a global leader in on-demand workforce solutions and integrated facility management (IFM), is pleased to announce its acquisition of Pesticide Pest Control Pte. Ltd., a Singapore-based pest control company with over 30 years of operational history.